MacroGenics Inc. Files 2024 10-K
Ticker: MGNX · Form: 10-K · Filed: 2025-03-20T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
MGNX filed its 2024 10-K. Full year results are in.
AI Summary
MacroGenics Inc. filed its 2024 10-K on March 20, 2025, reporting its fiscal year results ending December 31, 2024. The company, based in Rockville, MD, operates in the pharmaceutical preparations sector. Key financial details and business operations for the fiscal year are outlined in this comprehensive filing.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of MacroGenics' financial performance, strategic initiatives, and risk factors for the fiscal year 2024, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, MacroGenics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-20 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- MACROGENICS INC (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 2025-03-20 (date) — Filing Date
- Rockville, MD (location) — Business Address
- James Karrels (person) — Member
- Jeffrey Peters (person) — Member
FAQ
What was MacroGenics Inc.'s total revenue for the fiscal year ending December 31, 2024?
The filing indicates revenue from collaborative agreements and product sales for the fiscal year 2024, but specific total revenue figures are not provided in this header data.
What are the primary business segments of MacroGenics Inc. as detailed in the 10-K?
The filing mentions 'productCandidate' and 'Segment' as business areas, with specific focus on 'RevenueFromCollaborativeAgreements' and 'Product' sales, and 'ContractManufacturing'.
Who are the key individuals mentioned in relation to the company's reporting for the fiscal year 2024?
James Karrels and Jeffrey Peters are mentioned as members in relation to the reporting periods.
In which state was MacroGenics Inc. incorporated?
MacroGenics Inc. was incorporated in Delaware (DE).
What is the SIC code for MacroGenics Inc.?
The Standard Industrial Classification (SIC) code for MacroGenics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
From the Filing
0001125345-25-000042.txt : 20250320 0001125345-25-000042.hdr.sgml : 20250320 20250320160504 ACCESSION NUMBER: 0001125345-25-000042 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250320 DATE AS OF CHANGE: 20250320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MACROGENICS INC CENTRAL INDEX KEY: 0001125345 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36112 FILM NUMBER: 25756439 BUSINESS ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: Rockville STATE: MD ZIP: 20850 BUSINESS PHONE: 301-251-5172 MAIL ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 10-K 1 mgnx-20241231.htm 10-K mgnx-20241231 false 2024 FY 0001125345 364 364 iso4217:USD xbrli:shares iso4217:USD xbrli:shares mgnx:productCandidate mgnx:Segment xbrli:pure mgnx:performanceObligation 0001125345 2024-01-01 2024-12-31 0001125345 2024-06-28 0001125345 2025-03-14 0001125345 2024-10-01 2024-12-31 0001125345 mgnx:JamesKarrelsMember 2024-01-01 2024-12-31 0001125345 mgnx:JamesKarrelsMember 2024-10-01 2024-12-31 0001125345 mgnx:JamesKarrelsMember 2024-12-31 0001125345 mgnx:JeffreyPetersMember 2024-10-01 2024-12-31 0001125345 mgnx:JeffreyPetersMember 2024-01-01 2024-12-31 0001125345 mgnx:JeffreyPetersMember 2024-12-31 0001125345 2024-12-31 0001125345 2023-12-31 0001125345 mgnx:RevenueFromCollaborativeAgreementsMember 2024-01-01 2024-12-31 0001125345 mgnx:RevenueFromCollaborativeAgreementsMember 2023-01-01 2023-12-31 0001125345 mgnx:RevenueFromCollaborativeAgreementsMember 2022-01-01 2022-12-31 0001125345 us-gaap:ProductMember 2024-01-01 2024-12-31 0001125345 us-gaap:ProductMember 2023-01-01 2023-12-31 0001125345 us-gaap:ProductMember 2022-01-01 2022-12-31 0001125345 mgnx:ContractManufacturingMember 2024-01-01 2024-12-31 0001125345 mgnx:ContractManufacturingMember 2023-01-01 2023-12-31 0001125345 mgnx:ContractManufacturingMember 2022-01-01 2022-12-31 0001125345 mgnx:RevenueFromGovernmentAgreementsMember 2024-01-01 2024-12-31 0001125345 mgnx:RevenueFromGovernmentAgreementsMember 2023-01-01 2023-12-31 0001125345 mgnx:RevenueFromGovernmentAgreementsMember 2022-01-01 2022-12-31 0001125345 2023-01-01 2023-12-31 0001125345 2022-01-01 2022-12-31 0001125345 us-gaap:CommonStockMember 2021-12-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001125345 us-gaap:RetainedEarningsMember 2021-12-31 0001125345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001125345 2021-12-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001125345 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001125345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001125345 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001125345 us-gaap:CommonStockMember 2022-12-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001125345 us-gaap:RetainedEarningsMember 2022-12-31 0001125345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001125345 2022-12-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001125345 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001125345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001125345 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001125345 us-gaap:CommonStockMember 2023-12-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001125345 us-gaap:RetainedEarningsMember 2023-12-31 0001125345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001125345 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001125345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001125345 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31